Pharmacology Watch – March 1, 2017
March 1, 2017
View Issues
-
New Report Raises Red Flags About Antiviral Agents and the Possibility of Liver Failure
The Institute for Safe Medication Practices reported on 524 cases of liver failure in the past 12 months associated with direct-acting antiviral agents for treating hepatitis C.
-
Class Action Suit Accuses Pharmaceuticals of Fixing Prices
A class action lawsuit accuses insulin manufacturers of fixing prices and conspiring to increase the cost of their essential medication.
-
Approved Drug Demonstrates Efficacy in Battling Potent Bacterial Infection
Bezlotoxumab was associated with a substantially lower rate of recurrent C. difficile infection compared to placebo with a good safety profile.
-
Comparing First-line Treatments for C. difficile Infections
Vancomycin and metronidazole are both used as first-line treatment for C. difficile infections, but vancomycin may be superior in reducing 30-day mortality.
-
Promising Treatment for Multiple Sclerosis Closer to Approval
Ocrelizumab may be closer to approval for the treatment of progressive multiple sclerosis based on the recently published results of two studies.
-
FDA Action
The FDA has approved a second cyclase-C agonist for the treatment of chronic idiopathic constipation.